Featured Research

from universities, journals, and other organizations

Malaria vaccine candidate RTS,S reduces the risk of malaria by half in African children, study finds

Date:
October 18, 2011
Source:
University of North Carolina School of Medicine
Summary:
First results from a large-scale Phase III trial of RTS,S* show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile.

A child receives a vaccination at the UNC study site, George Joaki Centre in Lilongwe, Malawi.
Credit: Photo by Caitlin Kleiboer

First results from a large-scale Phase III trial of RTS,S, published online in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington.

Related Articles


Half the world's population is at risk of malaria. The disease is responsible for close to 800,000 deaths each year, most of whom are children under five in sub-Saharan Africa.

5 to 17 month-old children

The trial, conducted at 11 trial sites in seven countries across sub-Saharan Africa, including a UNC-led site in Lilongwe, Malawi, showed that three doses of RTS,S reduced the risk of children experiencing clinical malaria and severe malaria by 56 percent and 47 percent, respectively. This analysis was performed on data from the first 6,000 children aged 5 to 17 months, over a 12-month period following vaccination. Clinical malaria results in high fevers and chills. It can rapidly develop into severe malaria, typified by serious effects on the blood, brain, or kidneys that can prove fatal. These first Phase III results are in line with those from previous Phase II studies.

The widespread coverage of insecticide-treated bed nets (75 percent) in this study indicated that RTS,S can provide protection in addition to that already offered by existing malaria control interventions.

6 to 12 week-old infants

The trial is ongoing and efficacy and safety results in 6 to 12 week-old infants are expected by the end of 2012. These data will provide an understanding of the efficacy profile of the RTS,S malaria vaccine candidate in this age group, for both clinical and severe malaria.

Combined data in 6 to 12 week-old infants and 5 to 17 month-old children

An analysis of severe malaria episodes so far reported in all 15,460 infants and children enrolled in the trial at 6 weeks to 17 months of age has been performed. This analysis showed 35 percent efficacy over a follow-up period ranging between 0 and 22 months (average 11.5 months).

"The publication of the first results in children aged 5 to 17 months marks an important milestone in the development of RTS,S," said Irving Hoffman, PA, MPH, co-principal investigator at the Lilongwe site. "These results confirm findings from previous Phase II studies and support ongoing efforts to advance the development of this malaria vaccine candidate," said Hoffman, who is also associate professor of medicine in the UNC School of Medicine.

Long-term efficacy

The RTS,S malaria vaccine candidate is still under development. Further information about the longer-term protective effects of the vaccine, 30 months after the third dose, should be available by the end of 2014. This will provide evidence for national public health and regulatory authorities, as well as international public health organizations, to evaluate the benefits and risks of RTS,S.

Safety

The overall incidence of serious adverse events (SAEs) in this trial was comparable between the RTS,S candidate vaccine (18 percent) recipients and those receiving a control vaccine (22 percent)

Differences in rates of SAEs were observed between the vaccines groups for specific events, such as seizures and meningitis, and were higher in the malaria vaccine group. Seizures were considered to be related to fever and meningitis was considered unlikely to be vaccine-related. These events will continue to be monitored and additional information about the safety profile of the RTS,S malaria vaccine candidate will become available over the next three years.

"Making progress against this disease has been extremely difficult, and sadly, many have resigned themselves to malaria being a fact of life in Africa. This need not be the case," said Francis Martinson, MPH, PhD, co-principal investigator in Lilongwe and country director of UNC Project-Malawi. "Renewed interest in malaria by the international community, and scientific evidence such as that we are reporting today, should bring new hope that malaria can be controlled."

The vaccine is being developed in partnership by GSK and the PATH Malaria Vaccine Initiative (MVI), together with prominent African research centers. The partners are all represented on the Clinical Trials Partnership Committee, which is responsible for the conduct of the trial. Major funding for clinical development comes from a grant by the Bill & Melinda Gates Foundation to MVI.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. The RTS,S Clinical Trials Partnership. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine, 2011; DOI: 10.1056/NEJMoa1102287

Cite This Page:

University of North Carolina School of Medicine. "Malaria vaccine candidate RTS,S reduces the risk of malaria by half in African children, study finds." ScienceDaily. ScienceDaily, 18 October 2011. <www.sciencedaily.com/releases/2011/10/111018131334.htm>.
University of North Carolina School of Medicine. (2011, October 18). Malaria vaccine candidate RTS,S reduces the risk of malaria by half in African children, study finds. ScienceDaily. Retrieved April 25, 2015 from www.sciencedaily.com/releases/2011/10/111018131334.htm
University of North Carolina School of Medicine. "Malaria vaccine candidate RTS,S reduces the risk of malaria by half in African children, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/10/111018131334.htm (accessed April 25, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, April 25, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

85 Killed in Niger by Meningitis Since Start of Year

85 Killed in Niger by Meningitis Since Start of Year

AFP (Apr. 24, 2015) A meningitis outbreak in Niger has killed 85 people since the start of the year prompting authorities to close schools in the capital Niamey until Monday. Video provided by AFP
Powered by NewsLook.com
C-Section Births a Trend in Brazil

C-Section Births a Trend in Brazil

AFP (Apr. 24, 2015) More than half of Brazil&apos;s babies are born via cesarean section, as mothers and doctors opt for a faster and less painful experience despite the health risks. Duration: 02:02 Video provided by AFP
Powered by NewsLook.com
Anti-Malaria Jab Hope

Anti-Malaria Jab Hope

Reuters - News Video Online (Apr. 24, 2015) The world&apos;s first anti-malaria vaccine could get the go-ahead for use in Africa from October if approved by international regulators. Paul Chapman reports. Video provided by Reuters
Powered by NewsLook.com
3D Food Printing: The Meal of the Future?

3D Food Printing: The Meal of the Future?

AP (Apr. 23, 2015) Developers of 3D food printing hope the culinary technology will revolutionize the way we cook and eat. (April 23) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins